Compare Prospect Capital Corporation (PSEC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Sana Biotechnology Inc — how do they compare? Prospect Capital Corporation trades at $1.72 (market cap $974.22M), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Prospect Capital Corporation is the larger of the two by market cap, and Prospect Capital Corporation pays a 23.01% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Sana Biotechnology Inc for 23 Days on average.
| PSEC | SANA | |
|---|---|---|
Market Cap | $974.22M | $836.71M |
Volume | 5,779,996 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $3.05 | $5.92 |
52-Week Low | $1.82 | $2.68 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $2.73B | $749.96M |
Dividend Yield | 23.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.82, down 1.09% today, with a bearish technical outlook from moving averages. The company shows mixed fundamentals with a low P/B of 0.33 but concerning revenue volatility, including a -$407M revenue in 2025. Recent quarterly EPS has consistently beaten expectations, and the company maintains regular dividend distributions. Analyst sentiment is cautious with 55% hold ratings, while technical indicators show oversold conditions with RSI below 10.
PSEC presents a high-risk opportunity with a discounted valuation and strong dividend yield, but faces significant challenges from volatile revenue performance and negative cash flow. The stock's current technical weakness and mixed analyst consensus suggest cautious approach required despite attractive yield characteristics.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
